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Figure. Overall survival in HSCT patients with high risk TMA
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a dosing schedule adjusted to maintain a suppressed CH50
which correlated with a therapeutic eculizumab level of
>99mg/mL. Response was deﬁned as resolution of hemato-
logic TMA parameters, normalization of sC5b-9, and a 50%
increase in the cystatin C-estimated glomerular ﬁltration
rate (CystC GFR). Data were compared to historical controls
from our prospective observational study with the same
high-risk TMA features who did not receive eculizumab
(n¼11). In both cohorts, high-risk TMA was diagnosed pro-
spectively using uniform clinical and laboratory criteria.
Results: 12 of 18 (67%) patients treated with eculizumab
achieved resolution of TMA. Median number of eculizumab
doses given for therapy were 16 (range 4-38). All patients
required frequent drug dosing 2-3 times per week for at
least the ﬁrst 2 weeks to achieve and maintain therapeutic
eculizumab levels. Patients with sC5b-9 levels >488ng/mL
at diagnosis (normal <244ng/mL) required 11-13 days of
therapy to normalize sC5b-9 and to achieve terminal com-
plement blockade before clinical response could be
observed, while patients with sC5b-9 level 488 required
2-5 days to block complement. All responders were able to
discontinue therapy without TMA relapse with median
follow up time of 37 weeks (range 8-128 weeks). One
responder died from GVHD three months after resolution ofPrimary Disease Transplant Resistance Weeks of elevated
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HLH Allo RBMT NA 7TMA. Six patients (33%) who did not respond to therapy
died with active TMA after receiving median of 4 doses
(range 2-24) of eculizumab. We did not observe any in-
fections or toxicities attributed to eculizumab. Overall sur-
vival was signiﬁcantly better in the group treated with
eculizumab as compared to untreated historical controls
with high risk TMA (p¼0.002, Figure).
Conclusions: Terminal complement blockade by eculizumab
improves survival in patients with high risk TMA who
otherwise have a very poor outcome. Pharmacodynamic
monitoring is needed to optimize drug dosing to achieve
prompt complement blockade and clinical response. Therapy
can be safely discontinued after TMA is controlled.
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Background: Drug resistant cytomegalovirus (CMV)
has been described in pediatric hematopoietic stem cell
(HSCT) patients; however, clinical signiﬁcance is poorly
described.
Methods: With IRB approval we performed a retrospective
analysis of HSCT recipients with CMV reactivation between
January 2009 and February 2014. Per institution guidelines,
peripheral blood was screened twice weekly after transplant
via CMV polymerase chain reaction (PCR). Patients with
reactivation (>200 copies/ml) received pre-emptive therapy
with ganciclovir. Patients with neutropenia (ANC< 500/mcl)
received foscarnet. Indications for CMV drug resistance gene
testing included reactivation lasting beyond 2 weeks of
therapy, 10-fold rise in PCR or development of CMV disease.
Viracor IBT Laboratories performed PCR gene-sequencing
analysis for mutations of the UL97phototransferase and UL54
DNA polymerase genes.
Results: Of 34 patients with CMV reactivation, 5.8% (n¼2)
had drug resistant virus. One patient received only foscarnet
and had ganciclovir resistant virus. This patient had both
signiﬁcantly elevated and prolonged positive viral load. The
second patient was exposed to foscarnet, ganciclovir and
cidofovir prior to resistance testing and had virus resistant to
ganciclovir and cidofovir.
We hypothesize patients with CMV disease are at risk of
having drug resistant virus if they also have >20-fold rise in
viral copies and/or prolonged viremia. Five patients had
>20 fold increase in viral copies after starting anti-viral
therapy, one of which had ganciclovir resistant virus. The
second patient with drug resistant virus had only a 5-fold
rise in viral copies but failed to respond to anti-viral therapy
with persistent viremia 30 weeks from the start of anti-viralPCR Fold PCR increase Anti-Viral Therapies Disease
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Figure 1. RSV trend in pediatric HSCT recipients
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CMV disease. In contrast, 3 patients (8.8%) were not
screened or negative for resistant virus and had CMV
disease.
Discussion: Drug resistant CMV in pediatric HSCT re-
cipients is rare and associated morbidity is poorlyFigure 2. Demographics, risk factors ancharacterized. Anti-viral exposure may not be associated
with drug resistant virus in this population. Our data im-
plies a potential risk for community acquired ganciclovir
resistant virus. Both patients with drug resistant virus had
clinical disease suggesting patients with drug resistant
virus are at greater risk of developing CMV disease. A
prospective evaluation of gene mutation status at reac-
tivation, after anti-viral therapy, with elevated viral load
and with prolonged viremia is needed to better charac-
terize drug resistant CMV.306
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